A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Azathioprine (Azasan)

Purine Antimetabolite class · 6 generic manufacturers · 17 ANDAs filed at FDA.

First FDA approval1995-05-01
Generic availableYes · 6 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$29.7M in CY2024 Part D spend596K claims · 173K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.130/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.54
Across all dosage forms in distribution.
Highest NADAC
$8.89
Wide spread — brand-strength NDCs still in market.
Plans with PA
435 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Azathioprine used for?

Azathioprine is a Purine Antimetabolite medication tracked in Medicare Part D.

Is there a generic for Azathioprine?

Yes. 17 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Azathioprine?

Across 329 Part D plans, Azathioprine averages $2.54/unit (NADAC). Lowest available: $0.130/unit. Highest in distribution: $8.89/unit.

Is Azathioprine on the FDA shortage list?

No. Azathioprine is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Purine Antimetabolite1 alternative in D1
01
Cladribine
Brand: Mavenclad
Lowest NADAC
4Generic mfrs
$334.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.